Lv41
720 积分 2022-10-09 加入
Progress toward personalized management of stage II/III triple negative breast cancer
1个月前
已关闭
Progress toward personalized management of stage II/III triple negative breast cancer
1个月前
已关闭
Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
1个月前
已完结
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
1个月前
已完结
Deciphering the landscape of triple negative breast cancer from microenvironment dynamics and molecular insights to biomarker analysis and therapeutic modalities
1个月前
已完结
Advances in systemic therapies for triple negative breast cancer
1个月前
已完结
The treatment landscape of triple-negative breast cancer
3个月前
已完结
Triple negative breast cancer: what clinical progress have we seen in the last 5 years?
4个月前
已完结
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
4个月前
已完结
Prevalence and patient characteristics of familial hypercholesterolemia in a Chinese population aged 35–75 years: Results from China PEACE Million Persons Project
5个月前
已完结
皖公网安备34019202002308
